Loading…
Lobbying Spend
—
Filings
4
Firms Hired
1
Active Period
2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Affordable Prescriptions for Patients Act
2026 · third_quarter · Firm: TWINLOGIC STRATEGIES, LLP
Issues related to patents and generic drugs Monitor S. 1096 - patent settlements Issues relating to review of pharmaceutical patents in inter partes reviews Issues relating to the Patent Trial and Appeal Board Patent thickets - S. 1041 Skinny labeling issues Monitor issues relating to the Patent Eligibility Restoration Act Monitor issues relating to the PREVAIL Act
Client expense: — · Firm income: $40,000
Matched citations: S. 1041
Preserve Access to Affordable Generics and Biosimilars Act
2026 · third_quarter · Firm: TWINLOGIC STRATEGIES, LLP
Issues related to patents and generic drugs Monitor S. 1096 - patent settlements Issues relating to review of pharmaceutical patents in inter partes reviews Issues relating to the Patent Trial and Appeal Board Patent thickets - S. 1041 Skinny labeling issues Monitor issues relating to the Patent Eligibility Restoration Act Monitor issues relating to the PREVAIL Act
Client expense: — · Firm income: $40,000
Matched citations: S. 1096
Affordable Prescriptions for Patients Act
2026 · second_quarter · Firm: TWINLOGIC STRATEGIES, LLP
Issues related to patents and generic drugs Monitor S. 1096 - patent settlements Issues relating to review of pharmaceutical patents in inter partes reviews Issues relating to the Patent Trial and Appeal Board Patent thickets - S. 1041 Skinny labeling issues Monitor issues relating to the Patent Eligibility Restoration Act Monitor issues relating to the PREVAIL Act
Client expense: — · Firm income: $40,000
Matched citations: S. 1041
Preserve Access to Affordable Generics and Biosimilars Act
2026 · second_quarter · Firm: TWINLOGIC STRATEGIES, LLP
Issues related to patents and generic drugs Monitor S. 1096 - patent settlements Issues relating to review of pharmaceutical patents in inter partes reviews Issues relating to the Patent Trial and Appeal Board Patent thickets - S. 1041 Skinny labeling issues Monitor issues relating to the Patent Eligibility Restoration Act Monitor issues relating to the PREVAIL Act
Client expense: — · Firm income: $40,000
Matched citations: S. 1096
Affordable Prescriptions for Patients Act
2026 · first_quarter · Firm: TWINLOGIC STRATEGIES, LLP
Issues related to patents and generic drugs Monitor S. 1096 - patent settlements Issues relating to review of pharmaceutical patents in inter partes reviews Issues relating to the Patent Trial and Appeal Board Patent thickets - S. 1041 Skinny labeling issues Monitor issues relating to the Patent Eligibility Restoration Act Monitor issues relating to the PREVAIL Act
Client expense: — · Firm income: $30,000
Matched citations: S. 1041
Preserve Access to Affordable Generics and Biosimilars Act
2026 · first_quarter · Firm: TWINLOGIC STRATEGIES, LLP
Issues related to patents and generic drugs Monitor S. 1096 - patent settlements Issues relating to review of pharmaceutical patents in inter partes reviews Issues relating to the Patent Trial and Appeal Board Patent thickets - S. 1041 Skinny labeling issues Monitor issues relating to the Patent Eligibility Restoration Act Monitor issues relating to the PREVAIL Act
Client expense: — · Firm income: $30,000
Matched citations: S. 1096
Source: Senate LDA